

Special Issue

Rabies Vaccines and Immunoglobulins

Message from the Guest Editors

Rabies is a typically fatal but vaccine-preventable disease caused by infection with rabies virus (RABV) and other members of the *Lyssavirus* family. Rabies vaccines and immunoglobulins are essential for the prevention and control of the disease in human and animal populations. In this Special Issue, we invite submissions of original research or review articles to highlight the state of the art and future directions in the development of these biologics. Our scope encompasses use in humans or animals, for pre- or post-exposure prophylaxis or treatment. Topics of interest include (but are not limited to) safety, immunogenicity, and efficacy of current and next-generation rabies vaccines and immunoglobulins; delivery strategies for pre-exposure prophylaxis for domestic animal, wildlife or human populations; cost-effectiveness studies; thermostability; novel adjuvants; non-specific effects of vaccines; preclinical, clinical, or post-marketing studies of new products, regimens, or routes of administration; use of recombinant monoclonal antibodies for post-exposure prophylaxis or treatment.

Guest Editors

Prof. Dr. Darryn Knobel

School of Veterinary Medicine, Ross University, Basseterre, St Kitts, Saint Kitts and Nevis

Dr. Carlos Palacios

Instituto de Ciencia y Tecnología Dr. César Milstein, CONICET-Fundación Pablo Cassará, Ciudad de Buenos Aires, Argentina

Deadline for manuscript submissions

closed (31 October 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/150559

Vaccines

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).